Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy

Inclusion Criteria

• •1. Signed informed consent
• •2. Social security coverage
• •3. Age between 18 and 80 years
• •4. Histologically proven breast cancer, regardless of histological type or molecular subtype (triple negative, hormone-receptor positive, HER2+++), including inflammatory forms
• •5. Localised breast cancer with or without axillary or subclavicular lymph node involvement
• •6. Absence of bone or visceral metastasis on further evaluation (bone scintigraphy, chest X-ray, abdominal echocardiography or CT scan of the thorax, abdomen and pelvic area)
• •7. Treatment by neoadjuvant chemotherapy (treatment protocol at physician's discretion)
• •8. Patient amenable to receiving adjuvant therapy (chemotherapy, radiotherapy, hormone therapy, targeted therapy)
• •9. Breast surgery (breast-sparing or not) planned after neoadjuvant chemotherapy